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Statement of Problem:  What do we know from the supporting data?
• Bone loss: ISS (Table 1, Fig. 1); Skylab (single photon absorptiometry, Ca balance); Mir (DXA)
• Elevated bone resorption markers: ISS (Fig. 2); Skylab; multiple bed rest studies
• Elevated urinary Ca:  ISS (Fig. 4); Skylab; multiple bed rest studies
• Uncoupled remodeling:  ISS (Figs. 2,3); multiple bed rest studies
General 
1) What are the molecular biology details for bone loss in 
space?
2) Related to the above, what is the explanation for the large 
variability in response between individuals and bone 
sites?
Topics Related to Resistive Exercise Use in Space
Why do resorption markers remain elevated while         
improving bone homeostasis?
1) Why do formation and resorption markers appear to 
remain essentially uncoupled? Do bone markers represent 
regional metabolic conditions?
2) Is there a compartmental redistribution of bone with 
targeted high resistive exercise?
3) How can in-flight resistive exercise be made more 
efficient/efficacious?
4) Does resistive exercise impact frequency and severity of 
inflight injuries and ways to prevent?
Potential Research Areas
Conclusions
1) From a flight risk standpoint, the problem is considered 
manageable
2) Data show that exercise plus an anti-resorptive will be 
effective, reducing bone loss, bone resorption and urinary 
Ca excretion (lowering renal stone risk)
3) Targeted high resistive exercise alone can significantly 
attenuate bone loss but not necessarily completely
Table 1. QCT vBMD and FE Strength Changes
Pre-ARED (Low Resis Ex) vs ARED (High Resis Ex) vs 
ARED +  Alendronate, R + < 2 weeks
Bone Biomarker Changes
Fig. 2  NTX Changes 
Pre-ARED (Low Resis Ex) vs ARED (High Resis Ex) vs ARED+Alendronate
Pre-ARED 
Control 
(n=18)
ARED 
Control
(n=8)
Alendronate + 
ARED 
(n=7)
QCT BMD (g/cm3) % Change %Change %Change
Total Hip
Trabecular -13.6 ± 6.41 -7.6 ± 6.01 -1.1 ± 9.82
Cortical -3.2 ± 3.5 -2.6 ± 1.8 -0.6 ± 4.7
Trochanter
Trabecular -13.5 ± 6.51 -7.2 ± 6.61 -1.9 ± 9.92
Cortical -3.2 ± 3.31 -3.3 ± 2.71 -0.5 ± 5.0
Femoral Neck
Trabecular -15.0 ± 9.81 -15.7 ± 17.81 6.5 ± 14.82,3
Cortical -4.0 ± 5.5 -1.8 ± 2.8 -1.0 ± 4.8
Finite Element Strength (N)
Non-Linear Stance -9.5 ± 5.61 1.7 ± 7.9 1.9 ± 9.72
Non-Linear Fall -14.1 ± 8.11 -2.7 ± 5.8 0.8 ± 10.12
Fig. 1  DXA BMD Changes
Pre-ARED (Low Resis Ex) vs ARED (High Resis Ex) vs 
ARED+Alendronate, R<2 Weeks
1Pre vs. Post, P < 0.05
2ARED + Alendronate vs. Pre-ARED, P < 0.05
3ARED + Alendronate vs. ARED, P < 0.05
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Fig. 4  Urinary Ca Changes
Pre-ARED (Low Resis Ex) vs ARED (High Resis Ex) vs ARED+Alendronate
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Pre ARED n = 4 to 8; ARED n = 5; ARED + Alendronate n = 7
Pre ARED ARED ARED + Alendronate
*
* *
*
*Significant Diff. vs. Pre-Flight, P <0.05, with Bonferroni correction
Pre ARED data calculated from Smith paper 2012 JBMR
1Pre vs. Post, P < 0.05
2ARED + Alendronate vs. Pre-ARED, P < 0.05
3ARED + Alendronate vs. ARED, P < 0.05
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Topics Related to Pharmaceutical Use in Space
1) Drug stability for long missions
2) Operational plan needed, e.g., in cases of equipment 
failure or crew injury where exercise may not be possible
3) Suitability of other anti-resorptives (e.g., cathepsin K, 
Rank-L inhibitors)
4) Suitability of anabolic drugs 
Fig. 3  BSAP Changes
Pre-ARED (Low Resis Ex) vs ARED (High Resis Ex) vs ARED+Alendronate
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*Significant Diff. vs. Pre-Flight, P < 0.05, with Bonferroni correction (based on absolute data)
Pre ARED and ARED data calculated from Smith paper 2012 JBMR
Pre ARED n = 5 to 8; ARED n = 3 to 7; ARED + Alendronate n = 6 to 7
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